Chronic Idiopathic Constipation Treatment Market is Predicted to Procure USD 19.7 Bn by 2033, Grow at a CAGR of 7.5% | Fact.MR

According to Fact.MR, a market research and competitive intelligence company, the global chronic idiopathic constipation treatment market is worth $9.4 billion in 2023 and is expected to grow at a 7.5% CAGR from 2023 to 2033.

Chronic idiopathic constipation (CIC) is a type of constipation that lasts a long period and has no clear explanation. It is a widespread condition that affects a large proportion of the global population, with a higher frequency among the elderly.

The chronic idiopathic constipation treatment market is predicted to expand significantly in the future years. The market is being driven by the rising prevalence of CIC, more awareness of the ailment, and growing need for effective treatment alternatives.

Get Free Sample Report to Grow Your Profit Margin:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8517

Furthermore, the aging population, sedentary lifestyles, and dietary changes are all contributing to the growing burden of CIC, driving up demand for therapeutic solutions.

Fiber supplements, laxatives, stool softeners, and prokinetic drugs are popular pharmaceuticals used to control CIC. Furthermore, advances in digital health technology are influencing the future of chronic idiopathic constipation treatment. Mobile software, wearable gadgets, and remote monitoring technologies are being developed to assist patients in tracking their bowel movements, nutrition, and exercise routines, as well as providing individualized management recommendations for CIC.

Key Takeaways from Market Study

Global sales of chronic idiopathic constipation medications are estimated to reach $19.7 billion by 2033.
The US market is rapidly developing due to the presence of important industry players.
The increasing frequency of chronic idiopathic constipation among Japan's elderly population is driving up demand for chronic idiopathic constipation treatment treatments.
Germany is likely to be a lucrative market for chronic idiopathic constipation medicine makers due to its excellent healthcare infrastructure.

"Key market participants are working to create cutting-edge solutions that can deliver effective and safe treatment for chronic idiopathic constipation sufferers," says a Fact.MR analyst.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=8517

Competitive Landscape

According to Fact.MR, a market research and competitive intelligence firm, key players in the chronic idiopathic constipation treatment market are focusing on developing technologically advanced solutions, introducing new design products, obtaining regulatory clearances, and partnering with and acquiring other companies.

Leading businesses in the chronic idiopathic constipation treatment industry are currently seeking FDA clearance for newly developed drugs. Over the forecast period, obtaining FDA approval is expected to be one of the important focus areas for manufacturers of chronic idiopathic constipation drugs.

The FDA has just given the all-clear to several medications.

In February 2020, the FDA approved an osmotic laxative developed by Braintree Laboratories (Sebela) to treat adults with persistent idiopathic constipation.
In April 2020, Ironwood Pharmaceuticals, Inc. announced that the USPTO has issued certificates of approval for patent applications relating to the formulation of the 72 mcg dose of LINZESS.
In March 2020, the US Food and Drug Administration granted Sebela Pharmaceuticals, Inc. approval to market Pizensy (lactitol).

Recent Market Developments

In Japan, EA Pharma and Mochida Pharmaceutical introduced the successful chronic constipation drug 'Movicol HD' in May 2022.

In April 2022, the United States Food and Drug Administration (USFDA) authorized Ibsrela, a drug made by Ardelyx, Inc. This NHE3 inhibitor is prescribed to adult patients with IBS-C (irritable bowel syndrome with constipation).

Chronic Idiopathic Constipation Treatment Industry Research Segmentation

By Type:
Normal-transit Constipation
Slow-transit Constipation
By Therapy:
Pharmacological Therapies
Non-pharmacological Therapies
By Treatment:
Medication
Surgery
By Drug:
Serotonin-4 (5-Ht4) Receptor Agonist
Guanylate Cyclase-C Agonist
Laxatives
Stimulants
By Route of Administration:
Oral
Injectable
By End User:
Hospitals
Homecare
Specialty Clinics
By Region:
North America
Latin America
Europe
East Asia
South Asia & Oceania
MEA

𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://www.factmr.com/report/chronic-idiopathic-constipation-treatment-market

More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global chronic idiopathic constipation treatment market, presenting historical demand data (2018 to 2022) and forecast statistics for the period (2023 to 2033).

The study divulges essential insights on the market based on type (normal-transit constipation, slow-transit constipation), therapy (pharmacological therapies, non-pharmacological therapies), treatment (medication, surgery), drug (serotonin-4 (5-Ht4) receptor agonist, guanylate cyclase-C agonist, laxatives, stimulants), route of administration (oral, injectable), and end user (hospitals, homecare, specialty clinics), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.